Literature DB >> 12644961

Thalidomide: from tragedy to promise.

Roger von Moos1, Rahel Stolz, Thomas Cerny, Silke Gillessen.   

Abstract

Thalidomide is an immunomodulatory and antiangiogenic drug. Although the exact mechanism of action is not fully understood, it has been shown to be active in a variety of diseases. There are multiple trials going on to evaluate the optimal dose of thalidomide and the importance of combining thalidomide with other drugs. This review introduces the properties and putative mechanism of action of thalidomide and summarizes the most important clinical trials with this biological modifier.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12644961     DOI： 2003/05/smw-09947

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN： 0036-7672            Impact factor:   2.193


  12 in total

1.  Screening of antiangiogenic potential of twenty two marine invertebrate extracts of phylum Mollusca from South East Coast of India.

Authors:  Pankaj Gupta; Muthuvel Arumugam; Raj Vardhan Azad; Rohit Saxena; Supriyo Ghose; Nihar Ranjan Biswas; Thirumurthy Velpandian
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

2.  Salvage therapy for hepatocellular carcinoma with thalidomide.

Authors:  Tsang-En Wang; Chin-Roa Kao; Shee-Chan Lin; Wen-Hsiung Chang; Cheng-Hsin Chu; Johson Lin; Ruey-Kuen Hsieh
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

3.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

Review 4.  Thalidomide-a notorious sedative to a wonder anticancer drug.

Authors:  Shuang Zhou; Fengfei Wang; Tze-Chen Hsieh; Joseph M Wu; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

5.  A framework to identify gene expression profiles in a model of inflammation induced by lipopolysaccharide after treatment with thalidomide.

Authors:  Renata T Paiva; Alessandra M Saliba; Tatiana O Fulco; Jorgenilce de Souza Sales; Daniel Serra de Carvalho; Elizabeth P Sampaio; Ulisses G Lopes; Euzenir N Sarno; Flavio F Nobre
Journal:  BMC Res Notes       Date:  2012-06-13

Review 6.  Explaining human recreational use of 'pesticides': The neurotoxin regulation model of substance use vs. the hijack model and implications for age and sex differences in drug consumption.

Authors:  Edward H Hagen; Casey J Roulette; Roger J Sullivan
Journal:  Front Psychiatry       Date:  2013-11-05       Impact factor: 4.157

7.  Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia.

Authors:  G Colombo; F Bortolotti; V Chiapponi; F Buttini; F Sonvico; R Invernizzi; F Quaglia; C Danesino; F Pagella; P Russo; R Bettini; P Colombo; A Rossi
Journal:  Int J Pharm       Date:  2016-11-30       Impact factor: 5.875

8.  A HAND to TBX5 Explains the Link Between Thalidomide and Cardiac Diseases.

Authors:  Athar Khalil; Rachel Tanos; Nehmé El-Hachem; Mazen Kurban; Patrice Bouvagnet; Fadi Bitar; Georges Nemer
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

9.  Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage.

Authors:  Bing Wang; Pui-Kai Li; Jian-Xing Ma; Danyang Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-07-02       Impact factor: 4.799

Review 10.  Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Gabriella Nicolini; Marianna Monfrini; Arianna Scuteri
Journal:  Toxics       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.